European journal of haematology · 2026
Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data-Linkage Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mo Allison, Thao Le Thi Phuong, Wellard Cameron, Wood Erica M, Shortt Jake, McQuilten Zoe K
Аннотация
BACKGROUND: Real-world data on transfusion needs of patients with myelodysplastic syndromes (MDS), and the impacts of disease-modifying therapies (DMTs) are sparse. In 2011, 5-azacitidine became the first funded DMT for MDS and chronic myelomonocytic leukaemia (CMML) patients in Australia and national patient blood management (PBM) guidelines were published.
AIMS: Describe red blood cell transfusion (RBC-T) and platelet transfusion (PLT-T) burden in MDS/CMML and any changes since 2011.
METHOD: Retrospective longitudinal cohort study of all MDS/CMML patients in the state of Victoria (population 6.5 million) from 2009 to 2022, linking hospital admissions dataset, cancer and death registries.
RESULTS: 7043 patients (5715 MDS; 1328 CMML), with median follow-up 1.8 years (interquartile range [IQR]: 0.5-4.0 years), had 55 048 RBC-T and 10 749 PLT-T episodes. By 5 years post-diagnosis, patients had on average 14 RBC-T and 3 PLT-T admissions, with transfusion burden affected by MDS subtype. PLT-T were significantly higher post-2011 versus pre-2011 (0.8 more PLT-T admissions by 2 years, p < 0.001), with no difference in RBC-T admissions.
CONCLUSION: Since 2011, RBC-T burden has remained stable, but PLT-Ts have increased. Given the potential costs and limited PLT inventories, this impacts blood supply planning and highlights the need for research to optimise PLT-T in MDS/CMML patients.
AIMS: Describe red blood cell transfusion (RBC-T) and platelet transfusion (PLT-T) burden in MDS/CMML and any changes since 2011.
METHOD: Retrospective longitudinal cohort study of all MDS/CMML patients in the state of Victoria (population 6.5 million) from 2009 to 2022, linking hospital admissions dataset, cancer and death registries.
RESULTS: 7043 patients (5715 MDS; 1328 CMML), with median follow-up 1.8 years (interquartile range [IQR]: 0.5-4.0 years), had 55 048 RBC-T and 10 749 PLT-T episodes. By 5 years post-diagnosis, patients had on average 14 RBC-T and 3 PLT-T admissions, with transfusion burden affected by MDS subtype. PLT-T were significantly higher post-2011 versus pre-2011 (0.8 more PLT-T admissions by 2 years, p < 0.001), with no difference in RBC-T admissions.
CONCLUSION: Since 2011, RBC-T burden has remained stable, but PLT-Ts have increased. Given the potential costs and limited PLT inventories, this impacts blood supply planning and highlights the need for research to optimise PLT-T in MDS/CMML patients.